Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 4 of 4 results for desferrioxamine

  1. Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia [ID4015]

    In development [GID-TA11250] Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Chronic iron overload (in people with thalassaemia) - desferrioxamine, deferiprone and deferasirox [ID350]

    Discontinued [GID-TAG423]

    Technology appraisal guidance
    Discontinued

  3. Betibeglogene autotemcel for treating transfusion-dependent beta-thalassaemia [ID968]

    Discontinued [GID-TA10334]

    Technology appraisal guidance
    Discontinued

  4. Chronic kidney disease: assessment and management (NG203)

    This guideline covers care and treatment for people with, or at risk of, chronic kidney disease (CKD). It aims to prevent or delay the progression, and reduce the risk of complications and cardiovascular disease. It also covers managing anaemia and hyperphosphataemia associated with CKD.

    NICE guideline
    Last updated
    24 November 2021
    View recommendations

    Sections for NG203